Video

Antibody-Drug Conjugates in Ovarian Cancer Treatment

Author(s):

Bradley J. Monk, MD, FACS, FACOG,Robert L. Coleman, MD, FACOG, FACS

Dr Michael Birrer highlights updated data on antibody-drug conjugates in ovarian cancer treatment.

Related Videos
Kathleen N. Moore, MD, MS
Kathleen N. Moore, MD, MS
Jennifer Scalici, MD
Related Content
Lunresertib Plus Camonsertib in Endometrial, Ovarian Cancer | Image Credit: © Katsyarina - stock.adobe.com
December 19th 2024

Lunresertib Plus Camonsertib Produces Durable Responses in Advanced Endometrial, Ovarian Cancer

Vadim Gushchin, MD; Teresa Diaz-Montes, MD, MPH, FACOG
April 20th 2023

Gushchin and Diaz-Montes Describe QOL Outcomes After Cytoreduction and HIPEC in Ovarian Cancer

Ovarian Cancer_Dr Microbe - stock.adobe.com
December 10th 2024

Luveltamab Tazevibulin Produces Responses in Platinum-Resistant Ovarian Cancer

Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer
July 18th 2022

Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer

Premal Thaker, MD, MS
December 2nd 2024

IMNN-001 Plus Chemo Data Highlight Potential to Fill Unmet Need in Ovarian Cancer

November Recap
December 2nd 2024

Revisit Every OncLive On Air Episode From November 2024